Browse the corpus

Immunophenotyping is a laboratory technique that employs highly specific antibodies conjugated to detectable labels to identify and characterize cells based on their protein expression profiles. By targeting antigens expressed on the cell surface, in the cytoplasm, or in the nucleus, immunophenotyping enables classification of cell populations based on lineage, differentiation, activation status, and functional characteristics. In routine practice, this approach most commonly uses flow cytometry, in which fluorescently labeled antibodies are detected by light-scatter and fluorescence-emission signals as individual cells pass through focused laser beams. The resulting multiparametric data enable precise identification and categorization of normal and pathological cell populations and serve as the diagnostic foundation for a wide range of hematologic malignancies and immune-mediated disorders.[1][2] The ability of flow cytometry to determine the presence or absence of specific cell-surface markers underpins its diagnostic utility. Broad lineage-associated antigens, such as CD45 or CD56, facilitate the identification of major leukocyte subsets, whereas more refined marker combinations enable detailed subpopulation analysis. This capability is particularly valuable for evaluating leukemias, lymphomas, immunodeficiency states, and immune dysregulation syndromes, as well as for phenotypic characterization of neoplastic cell populations with prognostic and therapeutic implications.[3][4] Since its introduction into diagnostic pathology more than 3 decades ago, immunophenotyping has profoundly transformed the evaluation of hematologic and immune-related diseases. Early applications were limited to single- or dual-parameter analyses; however, advances in cytometric instrumentation, antibody development, and fluorochrome chemistry have driven the field toward high-dimensional, multiparametric analysis.[5] Contemporary flow cytometers, equipped with multiple excitation lasers and optimized detector arrays, routinely support the simultaneous assessment of 18 to 30 parameters per cell, allowing high-resolution interrogation of cellular heterogeneity at the single-cell level.[6]

Since its introduction into diagnostic pathology more than 3 decades ago, immunophenotyping has profoundly transformed the evaluation of hematologic and immune-related diseases. Early applications were limited to single- or dual-parameter analyses; however, advances in cytometric instrumentation, antibody development, and fluorochrome chemistry have driven the field toward high-dimensional, multiparametric analysis.[5] Contemporary flow cytometers, equipped with multiple excitation lasers and optimized detector arrays, routinely support the simultaneous assessment of 18 to 30 parameters per cell, allowing high-resolution interrogation of cellular heterogeneity at the single-cell level.[6] Complementary platforms have expanded immunophenotyping capability. Spectral flow cytometry captures the full emission spectra of fluorochromes, improving the resolution of overlapping signals and enabling highly multiplexed antibody panels with more than 40 markers.[7] Mass cytometry (cytometry by time-of-flight, [CyTOF]) further extends multiplexing capacity by replacing fluorochromes with heavy metal–tagged antibodies and using time-of-flight mass spectrometry for detection, thereby minimizing signal overlap and eliminating autofluorescence. These technologies enable comprehensive immune profiling in both clinical and research settings.[8][9] Additional methodologies continue to play important roles in specific diagnostic contexts. Image cytometry integrates immunophenotypic analysis with high-resolution imaging, providing combined phenotypic and morphologic information that is particularly useful when sample volumes are limited.[10] Immunohistochemistry remains indispensable for tissue-based analyses, preserving spatial architecture and microenvironmental context, and thus complementing suspension-based cytometric techniques.[11] As immunophenotyping technologies continue to evolve toward increasing complexity and dimensionality, rigorous standardization, quality control, and harmonization of analytical and interpretive practices are paramount.[12][13]

Immunophenotyping plays a critical role in the diagnosis, classification, and therapeutic monitoring of a wide range of hematologic malignancies, immune disorders, and transplant-related conditions. Accurate and timely immunophenotypic analysis is essential for guiding clinical decision-making, prognostication, and personalized treatment strategies. Effective use of immunophenotyping requires a coordinated, interprofessional approach to ensure patient-centered care and optimal clinical outcomes. Pathologists, hematologists, oncologists, transplant clinicians, laboratory scientists, nurses, pharmacists, and information technology professionals each contribute specialized expertise across the diagnostic and care continuum. Clinical and laboratory professionals involved in immunophenotyping must possess specialized technical and interpretive skills, including appropriate test selection, specimen handling, antibody panel design, data analysis, and clinical correlation. Laboratory scientists and pathologists are responsible for ensuring analytical accuracy, quality control, and compliance with regulatory and accreditation standards, while clinicians integrate immunophenotypic findings with clinical, morphologic, and molecular data to establish diagnoses and guide treatment. Nurses and phlebotomists play a vital role in preanalytical quality by ensuring proper specimen collection, labeling, transport, and patient preparation, thereby directly impacting test reliability. Pharmacists contribute to therapeutic decision-making by aligning immunophenotypic results with targeted therapies and monitoring treatment response and adverse effects. A strategic, evidence-based approach is required to standardize immunophenotyping workflows, minimize diagnostic variability, and reduce the risk of errors. Ethical principles, including informed consent, appropriate test use, data confidentiality, and transparent reporting of results, must guide all stages of testing and interpretation. Clear delineation of responsibilities among team members supports accountability and enhances efficiency, while effective interprofessional communication ensures that critical results are conveyed promptly and interpreted consistently. Structured reporting, interdisciplinary case discussions, and tumor board participation further strengthen collaborative decision-making.

A strategic, evidence-based approach is required to standardize immunophenotyping workflows, minimize diagnostic variability, and reduce the risk of errors. Ethical principles, including informed consent, appropriate test use, data confidentiality, and transparent reporting of results, must guide all stages of testing and interpretation. Clear delineation of responsibilities among team members supports accountability and enhances efficiency, while effective interprofessional communication ensures that critical results are conveyed promptly and interpreted consistently. Structured reporting, interdisciplinary case discussions, and tumor board participation further strengthen collaborative decision-making. Care coordination is particularly important in complex cases such as leukemia and lymphoma diagnosis, measurable residual disease monitoring, immune dysregulation syndromes, and transplant evaluation, where serial immunophenotyping results inform longitudinal care. By fostering collaboration, flattening traditional hierarchies, and recognizing the essential contributions of all healthcare professionals, interprofessional teams can enhance diagnostic accuracy, improve patient safety, and optimize outcomes. Through integrated teamwork, standardized processes, and continuous interprofessional education, immunophenotyping serves as a model for high-quality, patient-centered care delivery.